Cargando…
Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC patients indicate that sorafenib alone has only moderate antitumor efficacy, and could not inhibit disease metastasis and progressi...
Autores principales: | Liu, Jianhua, Liu, Yahui, Meng, Lingyu, Ji, Bai, Yang, Daqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479120/ https://www.ncbi.nlm.nih.gov/pubmed/28638267 http://dx.doi.org/10.7150/ijms.19033 |
Ejemplares similares
-
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
por: Liu, Jianhua, et al.
Publicado: (2017) -
Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma
por: Yang, Xuran, et al.
Publicado: (2018) -
Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells
por: Cai, Hongqiao, et al.
Publicado: (2019) -
Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017) -
Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells
por: Moon, Byul, et al.
Publicado: (2022)